In vivo experiments confirmed that the co‐administration of IDET and paclitaxel significantly suppresses tumor growth in TNBC models, accompanied by a marked reduction in phosphorylated STAT3 and Bcl‐2 expression, while exhibiting favorable systemic tolerance. The gene discussed is BCL2; the disease is neoplasm.